中等收入国家晚期前列腺癌的管理:2017年晚期前列腺癌共识会议的现实考量
马来西亚晚期前列腺癌共识会议(MyAPCCC 2018)评估APCCC 2017共识在中等收入国家的适用性,由22名专家(11名泌尿外科医生和11名肿瘤科医生)对101个预设问题进行匿名投票,其中23个问题在理想世界和现实世界两种设定下评估。多数投票结果与APCCC 2017一致;在证据水平低的有争议话题(如寡转移性疾病管理)未达成共识,在现实世界设定下对去势初治或去势抵抗转移性前列腺癌使用高成本药物未达成共识;所有专家组成员推荐在可获得时使用仿制药。
要点
- 多数MyAPCCC 2018投票结果与APCCC 2017一致。
- 寡转移性疾病管理等证据水平低的话题未达成共识。
- 现实世界设定下对转移性前列腺癌使用高成本药物未达成共识。
核心结论
- MyAPCCC 2018投票结果反映中等收入国家在现实世界设定下对晚期前列腺癌的管理,可作为本地临床实践的参考,并突出现代医疗的财务挑战。
研究设计与样本
- 马来西亚晚期前列腺癌共识会议(MyAPCCC 2018)由指导委员会选择和修改101个共识问题,包括来自APCCC 2017的91个问题和MyAPCCC 2018的10个新问题,其中23个问题在理想世界和现实世界两种设定下评估。
- 由22名专家(11名泌尿外科医生和11名肿瘤科医生)组成的专家组对101个预设问题进行匿名投票,最终投票结果与APCCC 2017结果进行比较。
主要发现
- MyAPCCC 2018的多数投票结果与APCCC 2017结果一致。
- 对于证据水平低的有争议话题(如寡转移性疾病的管理),未达成共识。
- 在现实世界设定下,对于去势初治或去势抵抗转移性前列腺癌使用高成本药物,未达成共识。
- 所有专家组成员推荐在可获得时使用仿制药。
关键数值与推荐
- 101个共识问题中,23个问题在理想世界和现实世界两种设定下评估。
- 专家组由11名泌尿外科医生和11名肿瘤科医生组成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the results of the Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC) 2018, held for assessing the generalizability of consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC 2017) to Malaysia, a middle-income country. METHODS: Six key sections were chosen: (1) high-risk localized and locally advanced prostate cancer, (2) oligometastatic prostate cancer, (3) castration-naïve prostate cancer, (4) castrate resistant prostate cancer, (5) use of osteoclast-targeted therapy and (6) global access to prostate cancer drugs. There were 101 consensus questions, consisting of 91 questions from APCCC 2017 and 10 new questions from MyAPCCC 2018, selected and modified by the steering committee; of which, 23 questions were assessed in both ideal world and real-world settings. A panel of 22 experts, comprising of 11 urologists and 11 oncologists, voted on 101 predefined questions anonymously. Final voting results were compared with the APCCC 2017 outcomes. RESULTS: Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic disease. No consensus was reached on using high-cost drugs in castration-naïve or castration-resistant metastatic prostate cancer in real-world settings. All panellists recommended using generic drugs when available. CONCLUSIONS: The MyAPCCC 2018 voting results reflect the management of advanced prostate cancer in a middle-income country in a real-world setting. These results may serve as a guide for local clinical practices and highlight the financial challenges in modern healthcare.
引用
- Saad M, Alip A, Lim J, et al. Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. BJU Int. 2019. PMID: 31077523. doi:10.1111/bju.14807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。